World EPA Congress
- 21 - 23 March 2023
- RAI Congress Centre, Amsterdam
Let’s meet at Booth 51
Join us at the the World EPA Congress where we’ll be sharing the latest insights from the Access Infinity team on industry hot topics.
Join us on Day 1, 11:45 to hear from our team on:
“What’s the state of market access performance tracking in 2023?”
Today’s market access professionals are working incredibly hard to secure the best price and broadest access for their brands. It’s no secret that there are often obstacles to overcome, not to mention rising expectations and targets that are putting the function under increased pressure to deliver.
With all this in mind, how can you improve the success of something that isn’t measured?
It’s a subject that’s close to our hearts at Access Infinity. We see first-hand the positive impact that effective KPI tracking has in helping teams achieve faster access and better prices for their products.
At this year’s EPA Congress, we’ll provide an overview of the state of market access performance today, focusing on:
- The role of market access performance tracking and why it’s important for your success
- How to plan your own launch goals and targets, with guidance on the most impactful KPIs and metrics
- How to assess and measure your global market access performance across a launch
- Why 2023 is your year to become a market access performance champion for your business.
Join the Access Infinity team at RAI Congress Centre Amsterdam 21st – 23rd March.
Meet our speakers
Shri Rao Mukku
Founding Director
Shri Rao Mukku is a Founding Director at Access Infinity and has 14+ years of consulting and industry experience. Shri worked at Merck as Global Director, MAP (Market Access and Pricing) and was responsible for Erbitux and other oncology products and at Lundbeck as ‘Pricing Specialist’ in the Global Pricing team.
Shri’s consulting experience includes launch pricing strategy, country and indication sequencing, qualitative research on value proposition development, value messaging, impact of clinical evidence generation on product value assessment, post LoE (loss of exclusivity) pricing strategy & assessment of new products for BD opportunities (in-and out-licensing). He has also established and/or led pricing and market access departments of different consulting companies such as Access Partnership & Double Helix Consulting.
Thomas Gilboy
Digital Solutions Product Owner
Thomas Gilboy is the Product Owner at Access Infinity for our Market Access Digital Tools. As Product Owner, he leads the product development and leads the product development
leads the product development
and “blue sky thinking” of what is possible within the digital space for Market Access.
Before Access Infinity, Tom worked for 10 years within Market Access in consulting and at ViiV. In consulting Tom delivered over 100 projects covering a broad range of Market Access topics from early pipeline decisions through to end of life cycle planning, across a broad range of therapy areas. At ViiV, Tom covered the successful European Market Access for one of their launching HIV brands.
Join us on Day 2, 14:55 to hear from our team on:
“Analogue analysis dos and don'ts"
Our presentation on day 2 will focus on the needs of early market access teams, taking a deeper dive into how to produce more accurate analysis and evidence to support a product’s launch strategy, at pace.
In today’s pharma companies, the Market Access and Pricing function is providing a vital bridge between clinical and commercial functions. Analogues need to be considered at every stage, so that influencing drivers for price and market access can be evaluated.
In this session, our Founding Director Shri Rao Mukku will explore best practices in analysing analogues, as well as uncover the common mistakes we see in industry, offering our advice for how to avoid them.
Join the Access Infinity team at RAI Congress Centre Amsterdam 21st – 23rd March.
Best practices in estimating pipeline product prices for early market access teams
It goes without saying that analogues are a great choice for robust evidence because they tell us what’s historically happened to products in similar situations. Of course, there is no perfect analogue that 100% meets your own product, so how do you choose which ones to analyse and review?
There’s much to consider and a lot at stake, not to mention the time pressures you’re facing to answer complex questions, at pace.
So how can early market access professionals take a holistic approach to finding the right analogues in the right time frame?
Our Product Owner Thomas Gilboy explores this at EPA Congress, taking a deeper dive into:
· The analogue analysis challenges faced by today’s early market access teams[LB1]
· How to produce more accurate analysis and evidence to support a product’s launch strategy
· How to pick up the pace of analogue analysis [LB2] so that you can respond rapidly and accurately to enquiries from the [launch?] team
Let’s meet in person
The World EPA Congress 2022 is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Amsterdam.
Meet us at Booth 20.
About Access Infinity
Access Infinity is the world leader of digital transformation in the Pharma Industry. We are a trusted provider of digital platforms and consulting services to leading pharma companies
Our products and services
The critical support you need to develop a successful value assessment and launch strategy.
- Pricing and launch strategy
- Evidence gap analysis
- Multi-indication price optimisation
Our cloud-based apps for rapid business intelligence, KPI tracking, access and evidence planning.
- Access Hub - Track KPIs
- Evidence Hub - Evidence Generation
- Nuro - HTA & Pricing Intelligence
We look forward to meeting you
The World EPA Congress 2023 is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Amsterdam.
Ahmed Edathodu is a Founding Director at Access Infinity. Having worked in senior positions within market access in Big Pharma and strategy consulting companies, Ahmed co-founded Access Infinity and has been instrumental in developing its global pricing and reimbursement practice. Prior to starting Access Infinity, he worked at Janssen Pharmaceuticals (Johnson and Johnson’s Pharmaceutical arm) where he supported the EMEA team in launching Rezolsta as well as and market access strategy planning for Janssen’s full HIV portfolio.